Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of multiple myeloma patents

Patents where

Current Assignee

Industry

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9713503 Surgical utility connector	Patent 9713503 was granted and assigned to Novartis on July, 2017 by the United States Patent and Trademark Office.	Novartis	Novartis	United States Patent and Trademark Office	9713503	July 25, 2017
‌ US Patent 7879010 Infusion set	Patent 7879010 was granted and assigned to Roche on February, 2011 by the United States Patent and Trademark Office.		Roche	United States Patent and Trademark Office	7879010	February 1, 2011
‌ US Patent 10072082 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10072082 was granted and assigned to Bristol-Myers Squibb on September, 2018 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10072082	September 11, 2018
‌ US Patent 8472630 Method and system for establishing cryptographic communications between a remote device and a medical device	Patent 8472630 was granted and assigned to Roche on June, 2013 by the United States Patent and Trademark Office.		Roche	United States Patent and Trademark Office	8472630	June 25, 2013
‌ US Patent 11642468 Medicament injection device with rotary encoder	Patent 11642468 was granted and assigned to Sanofi on May, 2023 by the United States Patent and Trademark Office.	Sanofi	Sanofi	United States Patent and Trademark Office	11642468	May 9, 2023
‌ US Patent 7582631 Substituted heterocyclic compounds and methods of use	Patent 7582631 was granted and assigned to Amgen on September, 2009 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	7582631	September 1, 2009
‌ US Patent 9072587 Surgical variable-angle illuminator	Patent 9072587 was granted and assigned to Novartis on July, 2015 by the United States Patent and Trademark Office.		Novartis	United States Patent and Trademark Office	9072587	July 7, 2015
‌ US Patent 6946079 Centrifugal filtration method for separating fibrin monomer from blood	Patent 6946079 was granted and assigned to Bristol-Myers Squibb on September, 2005 by the United States Patent and Trademark Office.		Bristol-Myers Squibb	United States Patent and Trademark Office	6946079	September 20, 2005
‌ US Patent 7332303 Product quality enhancement in mammalian cell culture processes for protein production	Patent 7332303 was granted and assigned to Bristol-Myers Squibb on February, 2008 by the United States Patent and Trademark Office.		Bristol-Myers Squibb	United States Patent and Trademark Office	7332303	February 19, 2008
‌ US Patent 8147728 Pad transfer printing of silicone hydrogel lenses using colored ink	Patent 8147728 was granted and assigned to Novartis on April, 2012 by the United States Patent and Trademark Office.		Novartis	United States Patent and Trademark Office	8147728	April 3, 2012
‌ US Patent 9517264 Human FGF receptor and β-Klotho binding proteins	Patent 9517264 was granted and assigned to Amgen on December, 2016 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	9517264	December 13, 2016
‌ US Patent 11650159 Method of predicting a performance characteristic of a plant or yeast hydrolysate and its use	Patent 11650159 was granted and assigned to Takeda Pharmaceutical Company on May, 2023 by the United States Patent and Trademark Office.	Takeda Pharmaceutical Company	Takeda Pharmaceutical Company	United States Patent and Trademark Office	11650159	May 16, 2023
‌ US Patent 11607451 Self-buffering antibody formulations	Patent 11607451 was granted and assigned to Amgen on March, 2023 by the United States Patent and Trademark Office.	Amgen	Amgen	United States Patent and Trademark Office	11607451	March 21, 2023
‌ US Patent 7833979 Toxin peptide therapeutic agents	Patent 7833979 was granted and assigned to Amgen on November, 2010 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	7833979	November 16, 2010
‌ US Patent 10569014 Device and method for making aseptic connections	Patent 10569014 was granted and assigned to Amgen on February, 2020 by the United States Patent and Trademark Office.	Amgen	Amgen	United States Patent and Trademark Office	10569014	February 25, 2020
‌ US Patent 11773106 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11773106 was granted and assigned to AbbVie Inc. on October, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11773106	October 3, 2023
‌ US Patent 11780848 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof	Patent 11780848 was granted and assigned to AbbVie Inc. on October, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11780848	October 10, 2023
‌ US Patent 10584170 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10584170 was granted and assigned to Bristol-Myers Squibb on March, 2020 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10584170	March 10, 2020
‌ US Patent 10138299 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10138299 was granted and assigned to Bristol-Myers Squibb on November, 2018 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10138299	November 27, 2018
‌ US Patent 7531511 Method for inducing angiogenesis or vascular perfusion in the myocardium comprising administering FGF-2	Patent 7531511 was granted and assigned to Novartis on May, 2009 by the United States Patent and Trademark Office.		Novartis	United States Patent and Trademark Office	7531511	May 12, 2009
‌ US Patent 7468390 Methods of treatment and pharmaceutical composition	Patent 7468390 was granted and assigned to Novartis on December, 2008 by the United States Patent and Trademark Office.		Novartis	United States Patent and Trademark Office	7468390	December 23, 2008
‌ US Patent 10266596 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10266596 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10266596	April 23, 2019
‌ US Patent 10266594 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10266594 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10266594	April 23, 2019
‌ US Patent 10266595 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10266595 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10266595	April 23, 2019
‌ US Patent 10323093 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10323093 was granted and assigned to Bristol-Myers Squibb on June, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10323093	June 18, 2019

...

Results per page:

10,087 results

0 selected

10,087 results

0 selected